UCB’s bimekizumab tops J&J’s Stelara in psoriasis studyThe first phase 3 data with UCB’s key pipeline drug bimekizumab show that it hit all its efficacy Share XUCB’s bimekizumab tops J&J’s Stelara in psoriasis studyhttps://pharmaphorum.com/news/ucbs-bimekizumab-tops-jjs-stelara-in-psoriasis-study/
Amgen stumps up $13.4bn to claim Otezla from CelgeneCelgene has the buyer it needed for Otezla, smoothing the way for its mega-merger with Bristol-Myers Squibb. Amgen Share XAmgen stumps up $13.4bn to claim Otezla from Celgenehttps://pharmaphorum.com/news/amgen-stumps-up-13-4bn-to-claim-otezla-from-celgene/
Novartis ups 2019 guidance after strong Q2Novartis has revised its guidance for 2019 upwards after a strong set of Q2 figures, with its psoriasis Share XNovartis ups 2019 guidance after strong Q2https://pharmaphorum.com/news/novartis-ups-2019-guidance-after-strong-q2/
BMS will shed Otezla to push Celgene takeover throughBristol-Myers Squibb has opted to divest big-selling psoriasis drug Otezla to smooth the passage of its $74 billion Share XBMS will shed Otezla to push Celgene takeover throughhttps://pharmaphorum.com/news/bms-will-shed-otezla-to-push-celgene-takeover-through/
Patient Insights: Severe psoriasis & eczemaHoward Chang has lived with severe psoriasis and atopic dermatitis for almost 40 years since childhood. Now a Share XPatient Insights: Severe psoriasis & eczemahttps://pharmaphorum.com/views-analysis-patients/patient-insights-severe-psoriasis-eczema/
AbbVie gets crucial US approval for psoriasis drug SkyriziWith one eye on life without its ageing $20 billion-a-year blockbuster Humira, AbbVie has got its psoriasis drug Share XAbbVie gets crucial US approval for psoriasis drug Skyrizihttps://pharmaphorum.com/news/abbvie-gets-crucial-us-approval-for-psoriasis-drug-skyrizi/
AbbVie’s psoriasis drug Skyrizi approved in JapanAbbVie’s hotly anticipated psoriasis drug Skyrizi (risankizumab) has been approved in Japan, the first country to okay this Share XAbbVie’s psoriasis drug Skyrizi approved in Japanhttps://pharmaphorum.com/news/abbvies-psoriasis-drug-skyrizi-approved-in-japan/
Novartis makes quality of life case for Cosentyx with new dataThere is increasing recognition that skin clearance scores may not be enough to win over patients and doctors Share XNovartis makes quality of life case for Cosentyx with new datahttps://pharmaphorum.com/news/novartis-makes-quality-of-life-case-for-cosentyx-with-new-data/
J&J’s Tremfya outperforms Novartis’ Cosentyx in psoriasisA large head-to-head study has shown Johnson & Johnson’s psoriasis drug Tremfya outperformed Novartis’ rival, Cosentyx, which had Share XJ&J’s Tremfya outperforms Novartis’ Cosentyx in psoriasishttps://pharmaphorum.com/news/jjs-tremfya-outperforms-novartis-cosentyx-in-psoriasis/
